Pulmonary Fibrosis Clinical Trials

DelveInsight’s analysis highlights that the Pulmonary Fibrosis pipeline features over 110 key companies actively developing 140+ treatment candidates for the condition.

Pulmonary Fibrosis Overview:

Pulmonary fibrosis (PF) is a chronic, progressive lung disease characterized by excessive extracellular matrix (ECM) accumulation and remodeling of lung tissue, leading to scarring, thickening, and impaired oxygen exchange. This results in gradual respiratory decline, with symptoms including persistent shortness of breath, dry cough, and fatigue. Radiographic imaging typically reveals distinct interstitial fibrosis patterns.

The condition arises from an interplay of genetic, environmental, and cellular factors. Central to its pathology is an abnormal wound-healing process — instead of resolving inflammation and restoring tissue, the body enters a cycle of ongoing fibrosis. Key molecular drivers such as transforming growth factor-beta (TGF-β) perpetuate fibroblast activation and collagen overproduction. This imbalance between repair and fibrosis underlies the progressive scarring that defines PF, making it a major focus for emerging therapeutic innovations.

Request for a detailed insights report on Pulmonary Fibrosis pipeline insights https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

The “Pulmonary Fibrosis Pipeline Insight 2025” report by DelveInsight offers an in-depth evaluation of the ongoing clinical research, developmental progress, and future growth opportunities within the Pulmonary Fibrosis Therapeutics Market.

Key Takeaways from the Pulmonary Fibrosis Pipeline Report

• DelveInsight’s Pulmonary Fibrosis pipeline report highlights a dynamic landscape, with over 110 companies actively advancing more than 140 investigational therapies for the treatment of Pulmonary Fibrosis.

• The FDA has granted Orphan Drug Designation to taladegib, a Hedgehog signaling inhibitor being investigated for idiopathic pulmonary fibrosis (IPF). In a Phase 2a study, taladegib demonstrated encouraging improvements in lung and pulmonary vessel volume based on advanced imaging biomarkers, with the Phase 2b WHISTLE-PF trial expected to complete enrollment by 2026.

• In January 2025, the FDA also granted Fast Track Designation to buloxibutid, an oral therapy in development for IPF, aiming to accelerate its review process.

• Leading companies such as Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, SRN-001, Wuhan Optics Valley, Canbiopharma Co., Ltd., Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., and Agomab Therapeutics are driving innovation in this space.

• Notable pipeline candidates in various stages of development include BMS-986278, LYT-100, AP01, ARO-MMP7, and VUM02, among others.

Pulmonary Fibrosis Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Fibrosis Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Fibrosis market.

Download our free sample page report on Pulmonary Fibrosis pipeline insights

Pulmonary Fibrosis Emerging Drugs

BMS-986278 – Bristol Myers Squibb

BMS-986278 is an oral small-molecule antagonist targeting the lysophosphatidic acid receptor 1 (LPA1), developed as a potential antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Since elevated LPA levels and activation of LPA signaling contribute significantly to fibrosis progression, BMS-986278 works as a potent, full LPA1 antagonist, effectively blocking signaling across Gi, Gq, G12, and β-arrestin pathways in both engineered human LPA1-expressing cells and primary human lung fibroblasts. The candidate is currently being evaluated in Phase III clinical trials for pulmonary fibrosis.

LYT-100 – PureTech Health

LYT-100 (deupirfenidone) is an investigational therapy being developed for idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disorder. It is a deuterated form of pirfenidone, engineered to maintain the established pharmacological benefits and therapeutic efficacy of pirfenidone while delivering an optimized pharmacokinetic (PK) profile. Clinical data indicate that LYT-100 offers improved tolerability, which may support longer treatment duration and enhanced disease management. The drug is currently in Phase II clinical trials for pulmonary fibrosis.

Pulmonary Fibrosis Companies

More than 110 companies are actively engaged in developing therapies for pulmonary fibrosis. Among these, Bristol-Myers Squibb has advanced its drug candidate to the most progressed stage of development—Phase III clinical trials.

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Request the Sample PDF to Get Detailed Insights About the Pulmonary Fibrosis Pipeline Reports Offerings

Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Pulmonary Fibrosis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Pulmonary Fibrosis Therapies and Key Companies: Pulmonary Fibrosis Clinical Trials and advancements

Pulmonary Fibrosis Pipeline Therapeutic Assessment

• Pulmonary Fibrosis Assessment by Product Type

• Pulmonary Fibrosis By Stage

• Pulmonary Fibrosis Assessment by Route of Administration

• Pulmonary Fibrosis Assessment by Molecule Type

Download Pulmonary Fibrosis Sample report to know in detail about the Pulmonary Fibrosis treatment market @ Pulmonary Fibrosis Therapeutic Assessment

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/